Jefferies Group Analysts Give Sanofi (SAN) a €72.00 Price Target

Jefferies Group set a €72.00 ($88.89) price objective on Sanofi (EPA:SAN) in a research note released on Friday morning. The firm currently has a neutral rating on the stock.

A number of other equities analysts have also recently weighed in on SAN. Deutsche Bank set a €93.00 ($114.81) price target on Sanofi and gave the stock a buy rating in a report on Friday, January 19th. Berenberg Bank set a €97.00 ($119.75) price target on Sanofi and gave the stock a neutral rating in a report on Monday, January 22nd. Barclays set a €65.00 ($80.25) target price on Sanofi and gave the stock a sell rating in a research note on Tuesday, January 23rd. Goldman Sachs set a €82.00 ($101.23) target price on Sanofi and gave the stock a neutral rating in a research note on Tuesday, January 23rd. Finally, S&P Global set a €78.00 ($96.30) target price on Sanofi and gave the stock a neutral rating in a research note on Tuesday, January 23rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have given a buy rating to the company. The company has an average rating of Hold and a consensus target price of €79.41 ($98.04).

How to Become a New Pot Stock Millionaire

EPA SAN opened at €66.17 ($81.69) on Friday. Sanofi has a twelve month low of €63.09 ($77.89) and a twelve month high of €92.97 ($114.78).

TRADEMARK VIOLATION NOTICE: This news story was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.chaffeybreeze.com/2018/04/16/jefferies-group-analysts-give-sanofi-san-a-72-00-price-target.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply